Pluristem Therapeutics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Yaky Yanay
- Full Time Employees
- 153
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Matam Advanced Technology Park, Building No. 5 Haifa Israel 3508409
- IPO Date
- Dec 10, 2007
- CIK
- 0001158780
- Website
- pluristem.com
- Similar Companies
- Business
- Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israeli biotechnology company engaged in the research, development, and manufacture of placenta-based cell therapy product candidates and cell-based solutions for pharmaceutical, food technology, and agricultural sectors. The company produces proprietary PLX cell therapies, including PLX-PAD composed of maternal mesenchymal stromal cells designed to treat inflammatory conditions, acute muscle injuries, peripheral artery disease, and acute respiratory distress syndrome; PLX-R18 composed of fetal mesenchymal-like cells targeting hematopoietic complications such as those following radiation exposure and hematopoietic cell transplantation; and an allogeneic MAIT cell therapy platform for cancer immunotherapy. In addition, Pluri develops cultivated meat, fish, and seafood products for food technology applications and alternative farming methods in agriculture. Pluri's technology platform centers on 3D cell expansion allowing large-scale, consistent manufacturing of cell therapy products. Recent major developments include Pluri's name change from Pluristem Therapeutics Inc. to Pluri Inc. in July 2022 and the advancement of serum-free media for cell cultivation that reduces contamination risks and dependency on third-party suppliers. The company is in late-stage clinical trials aiming for marketing approval of PLX therapies and has expanded its intellectual property portfolio with new patents on immune cell expansion technologies in the US and Israel. Strategic alliances include a collaboration with Bar-Ilan University to advance cancer immunotherapy and an exclusive agreement with Ukrainian biobank Hemafund to stockpile and develop PLX-R18 as a radiation countermeasure. Additionally, Pluri secured a $30 million equity investment from China-based Innovative Medical to support its development pipeline. Founded in 2001 and headquartered in Haifa, Israel, Pluri operates globally across the pharmaceutical, regenerative medicine, food-tech, and agritech industries. It holds a portfolio of over 140 patents granted in approximately 52 countries.
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery
Best Penny Stocks to Buy as January Ends? 4 to Watch
Best Penny Stocks to Buy Right Now? 3 For Your List in January
Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform
Pluristem (PSTI) Misses Study Goal to Treat COVID-Related ARDS
Pluristem CEO Issues Shareholder Update
Pluristem Appoints Prof. Varda Shalev MD and Mr.
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
Cathie Wood's ARK Invest Sells 194,000 Shares of Pluristem Therapeutics
Pluristem Stock is Trading Higher After €20M Non-Dilutive Funding from European Investment Bank
PSTI Stock: From $4.52 To Over $4.90 Pre-Market Explanation
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
ARKG: Potential Disruption For Healthcare And Pharma Industries
Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem's ARDS Associated With COVID-19 Program to Mexico
Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study
Pluristem - Moment Of Truth
Pluristem to Present Initial Results from Its Phase I HCT Study with PLX-R18 Demonstrating Safety and Efficacy at the ASH Annual Meeting